U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07221877) titled 'A Study to Evaluate the Effect of KarXT on Urological Safety' on Oct. 13.
Brief Summary: The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.
Study Start Date: Jan. 21, 2026
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Intervention:
DRUG: Xanomeline/trospium chloride
Specified dose on specified days
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Bristol-Myers Squibb
Disclaimer: Curated by HT Syndication....